---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-118906"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:31:08.131363+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elutia Q3 net sales $5.9M (-3.3%); EluPro adoption accelerates with 100+ VAC submissions

## Summary
- Overall Q3 net sales $5.9M, down 3.3% YoY; BioEnvelope sales down 12% to $2.3M as customers await EluPro.
- SimpliDerm sales up 19% to $3.1M; adjusted gross margin improved to 61% from 60%.
- Net income from cont. ops $1.3M driven by $12.7M non-cash warrant revaluation gain; adjusted EBITDA loss $2.9M.
- EluPro: first patient implant, over 100 VAC submissions, 36 accounts ordering; full commercial launch set for Jan 2025.
- Cash balance $25.7M as of Sep 30, 2024, includes $13.8M from warrant exercises in early Q3.

## SEC filing metadata
- accession: 0001104659-24-118906
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465924118906/0001104659-24-118906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465924118906/tm2428517d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-118906
- JSON: https://secwatch.observer/filing/0001104659-24-118906.json
- Plain text: https://secwatch.observer/filing/0001104659-24-118906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.